Impact of different diagnostic measures on drug class association with dementia progression risk: A longitudinal prospective cohort study

Medicine and Dentistry

• Prospective Cohort Study 100%
• Clinical Dementia Rating 100%
• Rating Scale 100%
• Mild Cognitive Impairment 80%
• Disease Exacerbation 40%
• Isotopes of Calcium 20%
• Selective Serotonin Reuptake Inhibitor 20%
• Calcium Ion 20%
• Reproducibility 20%
• Antihypertensive Agent 20%
• Glycon 20%
• Alzheimer's Disease 20%
• Parkinson's Disease 20%
• Antiplatelet 20%
• Functional Status 20%
• Angiotensin II 20%
• Channel Blocker 20%
• Proportional Hazards Model 20%
• Acetylsalicylic Acid 20%
• Adrenergic Receptor Blocking Agent 20%
• Anxiolytic 20%
• Nonsteroid Antiinflammatory Agent 20%
• Antihypertensive 20%
• Diuretics 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Prospective Cohort Study 100%
• Mild Cognitive Impairment 100%
• Disease Exacerbation 50%
• Acetylsalicylic Acid 25%
• Metformin 25%
• Channel Blocker 25%
• Non-Steroidal Anti-Inflammatory Drug 25%
• Anxiolytic 25%
• Antiplatelet 25%
• Alzheimer's Disease 25%
• Angiotensin II 25%
• Calcium Ion 25%
• Parkinson's Disease 25%
• Antihypertensive Agent 25%
• Adrenergic Receptor Blocking Agent 25%
• Selective Serotonin Reuptake Inhibitor 25%
• Functional Status 25%
• Antihypertensive 25%
• Diuretics 25%

Neuroscience

• Clinical Dementia Rating 100%
• Mild Cognitive Impairment 80%
• Metformin 20%
• Angiotensin II 20%
• Channel Blocker 20%
• Alzheimer's Disease 20%
• Non-Steroidal Anti-Inflammatory Drug 20%
• Anxiolytic 20%
• Parkinson's Disease 20%
• Antihypertensive Agent 20%
• Selective Serotonin Reuptake Inhibitor 20%
• Diuretic 20%